Why is the Nanosonics share price crashing 12% today?

What's going on with this infection prevention company's shares?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nanosonics Ltd (ASX: NAN) share price is having a day to forget on Monday.

In morning trade, the infection prevention company's shares are down 12% to $4.03.

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.

Image source: Getty Images

Why is the Nanosonics share price crashing?

Investors have been hitting the sell button on Monday after brokers responded negatively to the company's recent trading update.

One of those brokers was Goldman Sachs, which has reiterated its sell rating and $3.50 price target on the company's shares.

Goldman highlights that Nanosonics has started FY 2023 positively in respect to sales but elected not to comment on its operating costs or earnings. It said:

As expected, there was no update on Opex at the 4m mark, which remains a key question following the sharp increase in headcount and operational infrastructure required for the new US distribution model. As a reminder, FY23 opex guidance of +15-18% surprised consensus to the upside at the time (following the +28% growth in FY22, which had already included some pull-forward), and was a key driver of our -50-130bps EBIT margin revisions in August.

Overall, whilst capital revenue continues to run ahead of our expectations, we are less clear on the near/long-term consumables trajectory and the cost/margin profile, and we make no changes to our forecasts (FY23E revenue/EBIT $153m/$10m).

What else?

Over at Morgans, the broker has downgraded Nanosonics' shares to a hold rating with a $4.91 price target.

Its analysts made the move on valuation grounds following a strong gain by the Nanosonics share price over the last five to six weeks. It explained:

We recently upgraded our forecasts reflecting favourable currency moves and sit slightly above NAN's recent revenue guidance range of growth of 20% to 25%. Although the year has started well for NAN with revenue up 42%, we prefer to wait until the 1H23 results before adjusting any forecasts.

As a result our target price remains unchanged at A$4.91 and given the recent share price strength we move to a Hold rating (from Add).

Though, with the Nanosonics share price now trading sharply below this price target, it is possible that Morgans' analysts may soon see value emerging again.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics Limited. The Motley Fool Australia has positions in and has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy healthcare workers in a lab.
Healthcare Shares

Clarity Pharmaceuticals shares are up 12% today. Here's what's driving the move

Today's announcement moves Clarity a step closer towards commercialisation.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

Which ASX biotech's shares are rocketing higher on big US news?

This company has more than doubled in value over the past three months.

Read more »

A man with a wry smile on his face is shown close up behind ascending piles of coins as he places another coin on top of the tallest stack representing rising dividends
Healthcare Shares

Here's the dividend forecast out to 2030 for CSL shares

Can healthy dividends continue from CSL?

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Forget CSL shares, this ASX healthcare stock could double in value

Brokers see significantly more upside ahead for Pro Medicus.

Read more »

Lab worker puts hands in the air and dances around.
Healthcare Shares

CSL shares look primed to take off — Here's why

Business remains robust and brokers see ASX stock soaring up to 100%.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »